Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Hereditary hemorrhagic telangiectasia
Hereditary hemorrhagic telangiectasia
Hereditary hemorrhagic telangiectasia
Synonyms: HHT, Rendu-Osler disease, Rendu-Osler-Weber disease
Synonyms: HHT, Rendu-Osler disease, Rendu-Osler-Weber disease
Synonyms: HHT, Rendu-Osler disease, Rendu-Osler-Weber disease
Drug discovery
14
drugs
With orphan designations
Rare developmental defect during embryogenesis
Hereditary hemorrhagic telangiectasia
Overview
Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder caused by mutations in ENG, ACVRL1, or SMAD4 genes, leading to abnormal vasculature with telangiectases and arteriovenous malformations (AVMs). Clinical hallmarks include recurrent epistaxis (>90% of adults), mucocutaneous telangiectases, and visceral AVMs (lungs, brain, liver, GI tract). Complications range from chronic anemia to life-threatening strokes or hemorrhages. Diagnosis follows the Curaçao criteria. Management combines antiangiogenics (bevacizumab), antifibrinolytics (tranexamic acid), iron supplementation, and procedural interventions for acute bleeding [1][3][7][16].
Burden
Morbidity: 30–50% develop pulmonary, cerebral, or hepatic AVMs; 32% with HHT require iron infusions [4][9][14].
Mortality: Hazard ratio 2.03 vs. controls, driven by stroke, cerebral abscess, and hemorrhage [14][18].
Costs: 40% higher healthcare utilization vs. matched controls, driven by frequent transfusions, imaging, and hospitalizations [9][19].
Therapies
Systemic therapies: Bevacizumab (reduces transfusion needs by >80%) and tranexamic acid (17–54% epistaxis reduction) [3][10][15].
Anemia management: IV iron for severe deficiency; transfusions reserved for hemodynamic instability [10][15].
Procedural: Argon Plasma Coagulation for acute GI bleeds; anticoagulation individualized based on bleeding risk [3][5][10].
Categories: rare circulatory system diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare hepatic diseases, rare neurological diseases, rare ophthalmic disorders, rare respiratory diseases, rare skin diseases, rare systemic and rheumatological diseases
Research Papers
1,156 drug discovery papers about Hereditary hemorrhagic telangiectasia, with 1 first-in-class and 33 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,156 drug discovery papers about Hereditary hemorrhagic telangiectasia, with 1 first-in-class and 33 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
proteins
2025-10-16 | Nasal RADA16 hydrogel application decreases epistaxis severity scores in adults with hereditary hemorrhagic telangiectasia.
More than 90% of adults with hereditary hemorrhagic telangiectasia (HHT) experience epistaxis, which can be recurrent and cause significant morbidity. RADA16 is a self-assembling peptide hydrogel approved by the US Food and Drug Administration for hemostasis and wound healing. In this cohort study, we assessed the effectiveness of nasal RADA16 application in controlling HHT-related epistaxis. A retrospective chart review was performed on a cohort of adult patients who received nasal RADA16 without any other changes in treatment. Pre- and post-Epistaxis Severity Scores (ESS), hemoglobin, and hematocrit were collected to assess treatment response. Of the included patients (n = 22), there were 26 applications of RADA16. The cohort was 54.5% male and 86.4% White, had a mean age of 55.5 years, and had a predominantly ACVRL1 genotype (40.9%). Baseline mean ESS was 5.0 and decreased by an average of 2.0 at an average of 46.9 days after treatment, which is 2.8 times more than the minimal clinically important difference for ESS in HHT (0.71). The mean baseline hemoglobin (n = 13) and hematocrit (n = 10), were 11.3 g/dL and 37.5%, respectively, and did not exhibit significant changes after RADA16 application. No bleeding, pain, or allergic reactions occurred due to the application. Several patients reported mild nasal congestion. Our experience demonstrates that RADA16 can be considered as a safe epistaxis treatment modality for HHT that is easy to apply and does not require the operating suite.
2025-06-24 | Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling.
Pulmonary arterial hypertension (PAH) and hereditary hemorrhagic telangiectasia (HHT) are two distinct vascular diseases linked to impaired signaling through bone morphogenetic protein (BMP) receptor complexes in endothelial cells. Although BMP-9 plays a central role in activating this pathway by binding to ALK1 and BMPR-II, its precise function in the pulmonary microvasculature has remained unclear. In this study, we demonstrate a role for BMP-9 in regulating pulmonary vascular architecture and homeostasis. Our findings reveal that BMP-9 signaling intersects with VEGF pathways and contributes to the delicate balance between vascular growth and remodeling in the lungs. We also show that disruption of this pathway can shift vascular responses toward an HHT-like state, potentially altering disease susceptibility. These insights offer a unique perspective on how BMP-9 and ALK1 shape pulmonary vascular biology and suggest that targeting this axis could inform future strategies for treating complex vascular diseases such as PAH.
2024-10-01 | 7819 Hypoglycemia with Hereditary Hemorrhagic Telangiextsia in a Boy After Liver Transplantation
Abstract Disclosure: H. Miyagi: None. M. Igarashi: None. E. Tanimoto: None. R. Horikawa: None. Introduction: Hereditary hemorrhagic telangiectasia (HHT) causes arteriovenous malformation (AVM) in liver, lung, and brain. It is not clear whether it also causes hypoglycemia. We show a case of HHT combined with hypoglycemia after liver transplantation, improved by nutrition management and growth hormone treatment. Case: 11 months old boy born from a mother with HHT was diagnosed as having with AVM prenatally. He was once operated for the liver AVM but developed a new collateral circulation which caused severe heart failure and lead to liver transplantation. He showed severe growth retardation and malnutrition. His body weight was 4.6 kg and height were 60 cm (-5.8 SD) when he was 1 year old, and blood test showed low albumin for 3 g/dL (3.4 - 4.7 g/dL), and total protein for 4 g/dL (5.7 - 7.5 g/dL). Hypoglycemia was found while switching his nutrition from parenteral to enteral nutrition after operation. His insulin was under 0.3 µU/mL when his blood glucose was 49 mg/dL IGF1 was 17 ng/mL (ref.11 - 149 ng/mL), suggested growth hormone (GH) deficiency. GH stimulation test showed blunted response. GH treatment was started. Other pituitary hormones were within normal range. Nutritional support was added using high-calory milk. After GH treatment, IGF1 level increased to 87 ng/mL. GH and nutritional management improved not only his weight and height gain but also his glycemic control. Discussion: Hypoglycemia may be caused by both GHD and malnutrition. GHD and low IGF1 might be caused by malnutrition. Retesting GH secretion after improvement of nutrition is planned to clarify his pituitary function. Presentation: 6/2/2024
2024-03-01 | Abstract 2385 The role of the ALK1 protein in vascular disease and potential targetability in Crohn's disease
The ACVRL1 gene is highly expressed in endothelial cells and encodes the transmembrane protein activin receptor-like kinase 1 (ALK1), which is a type I cell-surface receptor serine/threonine kinase for the transforming growth factor-β (TGF-β) superfamily of ligands BMP9/GDF2 and BMP10. ALK1 comprises of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular kinase domain. Upon ligand binding, this receptor forms complexes with other TGF-β receptors, primarily BMP9 to activate intracellular downstream signaling pathways. The Smad pathway functions to regulate gene expression through transmitting nucleus signals from the TGFβ receptors. Signaling is transmitted by a cytoplasmic kinase domain of ALK1 by phosphorylating receptor-regulated Smad proteins (R-Smad proteins). Activated R-Smad proteins and the common-Smad (co-Smad) form a complex to regulate transcription of target genes together with cofactors. This pathway is essential for angiogenesis and vasculogenesis and a mutation can induce several vascular diseases. The Smad Pathway is also crucial for endothelial cell differentiation and homeostasis, which plays roles in Crohn's Disease. Differing mutations in the ACVRL1 gene can result in increased or decreased kinase activity as well as impaired ligand binding, disrupting of TGF-β signaling, and in some cases induce a rare genetic disorder known as Hereditary Hemorrhagic Telangiectasia (HHT). HHT is an inherited disorder characterized by abnormally formed blood vessels. TGF-β can act as both a tumor suppressor and a tumor promoter, and mutations or dysregulation of components in its pathway can lead to several types of cancer. In Crohn's disease patients, scientists were able to determine an increased risk of endoscopic relapse based on ALK1 levels. Additionally, activation of ALK1 has been shown to enhance colonic intestinal epithelial barrier integrity and function ex vivo in these studies. The Walton High School SMART team, with support from 3D molecular designs, has modeled ALK1 receptors to support testing of the ALK1 protein to develop potential therapies and interventions for Crohn's disease, HHT, and several cancers.
2023-03-31 | Data from ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth
<div>Abstract<p>Activin receptor–like kinase-1 (ALK1) is a type I, endothelial cell–specific member of the transforming growth factor-β superfamily of receptors known to play an essential role in modulating angiogenesis and vessel maintenance. In the present study, we sought to examine the angiogenic and tumorigenic effects mediated upon the inhibition of ALK1 signaling using a soluble chimeric protein (ALK1-Fc). Of 29 transforming growth factor-β–related ligands screened by surface plasmon resonance, only bone morphogenetic protein (BMP9) and BMP10 displayed high-affinity binding to ALK1-Fc. In cell-based assays, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate. In a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor–, fibroblast growth factor–, and BMP10-mediated vessel formation. The growth of B16 melanoma explants was also inhibited significantly by ALK1-Fc in this assay. Finally, ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells. These data show the efficacy of chimeric ALK1-Fc proteins in mitigating vessel formation and support the view that ALK1-Fc is a powerful antiangiogenic agent capable of blocking vascularization. Mol Cancer Ther; 9(2); 379–</p></div>
small molecules
2026-09-24 | Decreased Endothelial Cell Retinoic Acid Signaling Accelerates Progression of Single Ventricle Pulmonary Vascular Malformations.
Pulmonary vascular malformations (PVMs) are vascular complications that universally develop in patients with single ventricle congenital heart disease after Glenn surgery, yet the pathogenesis of single ventricle PVMs remains unknown. Using a surgical rat model of Glenn circulation, single-cell RNA sequencing (scRNAseq) on whole lung samples identified dramatic endothelial cell (EC) gene expression changes post-surgery, including decreased all-trans retinoic acid (ATRA) signaling. Many gene expression differences (∼17% of all EC differentially expressed genes), including decreased ATRA signaling, were shared with 2 independent models of hereditary hemorrhagic telangiectasia arteriovenous malformations (AVMs). Subsequent dietary modification of vitamin A (Vit A) intake in rats, identified that dietary deficiency of Vit A increased PVM shunting severity, which was mitigated with excess dietary Vit A intake. Collectively, our study of post-Glenn PVMs identified shared patho-mechanisms with hereditary hemorrhagic telangiectasia AVMs, including decreased EC ATRA signaling, which is a novel potential target for treating AVMs.
2026-09-23 | Current Paradigm Shift in the Treatment of Hereditary Hemorrhagic Telangiectasia: A Narrative Review.
Background Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant, multisystem vascular disorder characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs). Pathogenic variants in ENG (endoglin), ACVRL1 (activin receptor-like kinase 1, ALK1), and SMAD4 (SMAD family member 4) disrupt signaling in the bone morphogenetic protein (BMP) 9/10 and transforming growth factor-beta (TGF-β) pathways, resulting in dysregulated angiogenesis and excess vascular endothelial growth factor (VEGF) activity. Clinically, HHT most commonly presents with recurrent epistaxis and chronic gastrointestinal (GI) bleeding, frequently leading to iron deficiency anemia and reduced quality of life (QoL). Complications from visceral AVMs involving the lungs, brain, and liver may also occur. Early diagnosis and systematic screening are essential to reduce preventable morbidity. Methods This narrative review synthesizes current primary literature on the diagnosis, screening, and treatment of HHT, with particular emphasis on evolving systemic therapies, supportive care strategies, and procedural interventions. Evidence from international guidelines, randomized trials, observational cohort studies, and narrowly focused systematic reviews was evaluated to summarize contemporary management approaches. Results HHT diagnosis is made with the Curaçao clinical criteria, genetic testing, and targeted imaging to identify visceral vascular malformations. Screening recommendations emphasize early detection of pulmonary and cerebral AVMs and ongoing surveillance for anemia and other complications. Therapeutic strategies increasingly prioritize systemic therapy over repeated local procedures. Antiangiogenic agents including intravenous bevacizumab, pomalidomide, thalidomide, and oral pazopanib have demonstrated efficacy in reducing bleeding severity, improving hemoglobin levels, and decreasing transfusion requirements in moderate-to-severe disease. Supportive care remains foundational and includes iron replacement, selective blood transfusion, routine monitoring, and assessment of patient-reported QoL. In patients with refractory epistaxis, surgical interventions such as septodermoplasty or nasal closure may provide durable bleeding control. Endovascular and neurosurgical management may also be required for selected vascular complications. Conclusions Management of HHT is undergoing a paradigm shift toward mechanism-based systemic therapy integrated with multidisciplinary care. Advances in antiangiogenic and precision-medicine approaches are improving bleeding control and long-term outcomes. Early recognition, comprehensive screening, individualized therapy, and coordinated management across specialties are critical for optimizing care in this complex multisystem disease.
2026-09-07 | Solving an enigma: the BMP-9/10 axis as a key regulator of pulmonary vascular resilience.
The circulating ligands bone morphogenetic protein (BMP)-9 and BMP-10 are emerging as dual regulators of pulmonary and systemic vascular biology. Acting through activin receptor-like kinase 1 (ALK1), BMP receptor type II (BMPRII) and endoglin receptor complexes, they maintain endothelial quiescence and vascular tone under physiological conditions. Yet, the same axis can turn pathogenic when its intensity, timing or cellular context are altered. We propose viewing BMP-9/10 not as a linear protective pathway but as a bimodal system in which both deficiency and hyperactivation disrupt vascular homeostasis, leading to distinct phenotypes such as obstructive pulmonary arterial remodeling in pulmonary arterial hypertension (PAH), intrapulmonary vasodilatation in hepatopulmonary syndrome (HPS), and arteriovenous shunting in hereditary haemorrhagic telangiectasia (HHT). The clinical success of sotatercept, an activin signaling inhibitor with partial BMP-ligand trap properties, underscores the translational potential of therapeutically "retuning" this pathway rather than globally enhancing it. Understanding when BMP-9/10 signaling protects and when it becomes pathogenic will be crucial for designing next-generation interventions that stabilize, instead of destabilize, pulmonary vascular integrity.
2026-09-01 | Interventional Radiology Management of Vascular Anomalies.
Vascular anomalies span a wide biological spectrum, from self-involuting infantile hemangiomas to life-threatening arteriovenous malformations. This review focuses on the conditions most commonly managed by interventional radiology, organized within the 2025 International Society for the Study of Vascular Anomalies classification framework. It covers the principles and agents of sclerotherapy for venous and lymphatic malformations, including comparative evidence for sclerosing agents, and embolization strategies for arteriovenous malformations and hereditary hemorrhagic telangiectasia -related pulmonary arteriovenous malformations. Also reviewed is the role of cryoablation in fibroadipose vascular anomaly, complex lymphatic anomaly management and the emerging techniques of bleomycin electrosclerotherapy and bleomycin electroembolotherapy.
2026-08-21 | Systemic therapies in hereditary hemorrhagic telangiectasia: Current evidence and emerging targets.
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant vascular disorder characterized by mucocutaneous telangiectases and visceral vascular malformations, leading to recurrent bleeding, iron-deficiency anemia, and organ complications. Pulmonary, cerebral, and hepatic involvement are major determinants of morbidity and mortality. Management has traditionally relied on local and interventional approaches, which are largely palliative and do not address underlying disease mechanisms. New insights in HHT pathophysiology, particularly in the dysregulated BMP9-BMP10/ENG/ALK1 pathway, which is fundamental to the angiogenesis process, have enabled the development of targeted systemic therapies. Although no systemic drug is specifically approved for HHT, antifibrinolytics, anti-angiogenic agents, mTOR and AKT inhibitors, and immunomodulatory drugs have shown variable efficacy in selected patients. This review summarizes current evidence on systemic therapies and ongoing clinical trials, highlighting their potential to complement existing strategies and move toward disease-modifying approaches.
gene therapies
2026-08-14 | Brain Abscess as the Initial Manifestation of Hereditary Hemorrhagic Telangiectasia in a Child.
Brain abscess secondary to pulmonary arteriovenous malformation is rare in children and may be the first manifestation of hereditary hemorrhagic telangiectasia (HHT). We retrospectively reviewed the clinical presentation, laboratory findings, imaging examinations, and diagnostic process of a child with brain abscess associated with pulmonary arteriovenous malformation and HHT. A 12-year-old boy presented with fever, headache, and limb weakness. Brain abscess was diagnosed, and antimicrobial therapy was initiated. Laboratory testing revealed fungal infection and erythrocytosis. Further evaluation identified a pulmonary arteriovenous malformation. Although the family history was initially unremarkable, physical examination revealed facial telangiectasia, recurrent epistaxis, and digital clubbing in his father, fulfilling the Curaçao criteria for HHT. Right-to-left shunt should be considered in children with brain abscess of unclear origin. Early recognition of underlying HHT is critical for timely diagnosis and management.
2026-07-07 | Expected survival is decreased in hereditary hemorrhagic telangiectasia: Results from a population-based registry study.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant genetic disorder associated with substantial morbidity. The aim of this study was to estimate mortality in a country without centralized national care for HHT patients. Moreover, we identified causes of death and estimated the prevalence of HHT in Sweden. The Swedish National Patient Register (NPR) was used to identify individuals with HHT using the International Classification of Diseases (ICD) code I78.0. Cases included all individuals with this code between January 1, 2001 and December 31, 2003 (n = 393). Five age- and gender-matched controls from the general population were selected by Statistics Sweden (SCB) (n = 1965). Cases and controls were followed for survival until 2018 using the Swedish National Cause of Death Register (DORS). To calculate prevalence, we identified all individuals with the ICD code I78.0 in the NPR over 12 years, from January 1, 2007 to December 30, 2018. Life expectancy for cases with HHT after age 30 was estimated at 73.0 (68.0-77.2) compared to 80.5 (79.1-82.0) years for controls. Ischemic heart diseases, diseases of arteries, arterioles, capillaries, and liver diseases were significantly more common causes of death among HHT patients. The prevalence of HHT was estimated at 9.3 per 100,000 over the 12 years. HHT in Sweden is associated with markedly shorter expected survival compared to the general population, and known complications of HHT are among the most common causes of death. The estimated prevalence of HHT in Sweden was relatively low, possibly due to underdiagnosis of those with milder symptoms.
2026-06-30 | When Phenotype Outspeaks Genotype: Uncommon Vascular Anomalies in Suspected Hereditary Hemorrhagic Telangiectasia Despite Negative Genetic Testing.
Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder characterized by abnormal blood vessel formation involving the skin and visceral organs. Establishing the diagnosis can be challenging, particularly in the absence of classic clinical manifestations or confirmatory genetic findings. We report the case of a 42-year-old woman who presented with acute epigastric pain and was found to have extensive vascular abnormalities involving the liver, lungs, aorta, and mesenteric circulation. She had no history of recurrent epistaxis, mucocutaneous telangiectasias, or family history of vascular disease, and genetic testing for known vascular disorders was negative. Despite the absence of typical clinical and genetic features, the distribution and extent of vascular involvement raised a strong suspicion for underlying HHT. This case highlights the potential for a broader phenotypic spectrum of HHT and underscores the limitations of current diagnostic criteria and genetic testing approaches.
2026-06-29 | Atypical Presentation of Hereditary Hemorrhagic Telangiectasia Without Recurrent Epistaxis Leading to Delayed Diagnosis
Objective:Unusual clinical course Background:Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disorder characterized by multisystem arteriovenous malformations (AVMs).The earliest symptoms often appear in childhood and typically encompass recurrent epistaxis.Severe outcomes, including cerebral hemorrhage and thrombotic complications, can increase morbidity and mortality.HHT is estimated to have near-complete penetrance, such that 97% of patients exhibit symptoms by age 60. Case Report:A 71-year-old man presented with a 1-month history of progressive shortness of breath, fatigue, dizziness, and lower-extremity edema.Further evaluation revealed severe iron-deficiency anemia (hemoglobin 6.4 g/dL, serum iron 21 µg/dL, total iron-binding capacity 462 µg/dL, transferrin saturation ~ 5%, and ferritin 13 ng/mL).He received 4 units of packed red blood cells, resulting in symptomatic improvement.Imaging did not identify any additional visceral malformations; follow-up esophagogastroduodenoscopy and colonoscopy findings were normal.Despite negative endoscopic findings, intermittent occult gastrointestinal blood loss remained the leading consideration given his prior history of bleeding gastrointestinal AVMs and laboratory findings consistent with iron-deficiency anemia.Capsule endoscopy-recommended to screen for small-bowel telangiectasias-was deferred.His medical history was notable for a delayed diagnosis of HHT.He remained clinically asymptomatic until age 67, when he developed spontaneous bilateral subdural hematomas and gastrointestinal bleeding. Conclusions:This case highlights delayed recognition of HHT in the absence of recurrent epistaxis, followed by serious intracranial and gastrointestinal complications.Overreliance on classic mucocutaneous features may contribute to diagnostic delay.Clinicians should consider HHT in older adults with otherwise unexplained AVM-related hemorrhage or anemia to facilitate timely screening and management.
2026-06-25 | A Novel Frameshift Variant of the ACVRL1 Gene in a Korean Family with Hereditary Hemorrhagic Telangiectasia Type 2: A Case Report
Beom Joon Kim, M.D., Woo Jin Shin, M.D., Hyunji Kim, M.D., Soohyun Seo, M.D., Anna Cho, M.D., Sook-Hyang Jeong, M.D., Kyoung Un Park, M.D.. Lab Med Online 2026;16:258-63. https://doi.org/10.47429/lmo.2026.16.3.258
antibodies
2026-09-29 | Severe Recurrent Gastrointestinal Bleeding Leading to the Diagnosis of Hereditary Hemorrhagic Telangiectasia: Clinical Response to Systemic Bevacizumab in a Case Report and Narrative Review.
Hereditary hemorrhagic telangiectasia (HHT), or Rendu-Osler-Weber disease, is an inherited vascular disorder that may cause severe gastrointestinal bleeding, particularly at an advanced age. The management of diffuse and recurrent gastrointestinal involvement may remain challenging despite repeated endoscopic treatments. We report the case of a 62-year-old woman with recurrent epistaxis since childhood, nasal and cutaneous telangiectases, and severe recurrent gastrointestinal bleeding related to multiple gastric, duodenal, jejunal, and more distal small-bowel telangiectases. A definite diagnosis of HHT was established based on the presence of three Curaçao criteria. During the two years preceding systemic therapy, the patient required 11 hospitalizations, repeated packed red blood cell transfusions, intravenous iron infusions, and 13 sessions of argon plasma coagulation. Intravenous bevacizumab was initiated at a dose of 5 mg/kg every 15 days for six induction cycles, followed by 5 mg/kg every four weeks as maintenance therapy. During one year of follow-up, the patient remained free of gastrointestinal bleeding for the first six months. The first recurrence occurred during the seventh month. Three separate hospitalizations for recurrent bleeding were observed during the year following bevacizumab initiation, compared with 11 during the preceding two years. The two most recent episodes were associated with less severe anemia than the most severe episodes before treatment. Qualitative endoscopic improvement, with an apparent reduction in the number and prominence of antral telangiectases, was also observed. No significant bevacizumab-related adverse events were identified. In this patient with severe HHT-related gastrointestinal involvement, systemic bevacizumab was associated with a clinically meaningful reduction in the overall bleeding burden. This case highlights the importance of considering HHT in patients with multiple or recurrent gastrointestinal telangiectases associated with epistaxis and mucocutaneous telangiectases.
2026-09-11 | A microphysiological system HHT-on-a-chip platform recapitulates patient vascular lesions.
Hereditary Hemorrhagic Telangiectasia (HHT) is a rare congenital disease in which fragile vascular malformations (VM) focally develop in multiple organs. There are few treatment options and no cure. HHT patients inherit loss-of-function mutations affecting Alk1-Eng signaling; however, why this manifests as VMs remains poorly understood. Here we have developed a fully human cell-based microphysiological system of perfused vasculature in which inducible shRNA controls endogenous Alk1 in primary endothelial cells (EC). Resulting VMs develop over several days, recapitulate patient VM appearance, and require only a subpopulation of Alk1-deficient EC to trigger lesions. Single-cell transcriptomics suggests microvessel pruning and regression contribute to VM, while loss of PDGFB implicates mural cell recruitment. Finally, pharmacological VEGF/VEGFR inhibition blocks lesion formation. In summary, we have developed an HHT-on-a-chip model that faithfully reproduces HHT patient lesions and that can be used to better understand HHT disease biology and identify potential new HHT drugs.
2026-09-11 | Efficacy and Safety of Various Medications in the Treatment of Hereditary Hemorrhagic Telangiectasia Epistaxis.
To compare the efficacy and safety of pharmacologic therapies for spontaneous epistaxis in hereditary hemorrhagic telangiectasia (HHT). PubMed, Scopus, Embase, Web of Science, and the Cochrane Library were systematically searched up to August 2025. Eligible randomized controlled trials evaluating bevacizumab, doxycycline, tranexamic acid, or β-blockers versus placebo or standard care were included. Outcomes included epistaxis frequency and duration, hemoglobin (Hb), epistaxis severity score (ESS), transfusion or emergent-care requirements, quality of life (QOL), and adverse events. Tranexamic acid did not significantly reduce epistaxis duration or frequency or improve Hb, and it did not change transfusion or emergent-care needs, but it increased diarrhea (odds ratio 3.8, 95% confidence interval [CI] [1.7; 8.5]). Bevacizumab produced a modest reduction in epistaxis frequency (standardized mean difference -0.25, 95% CI [-0.47; -0.02]), without significant effects on duration, ESS, Hb, or QOL. Doxycycline showed no significant benefit for duration or frequency. Topical or systemic β-blockers did not significantly affect ESS, QOL, Hb, or overall adverse events. Across agents, between-study heterogeneity was generally low to moderate and CIs were wide, reflecting limited sample sizes. No pharmacologic agent demonstrated consistent, clinically robust superiority over placebo across primary endpoints. Bevacizumab may modestly reduce bleeding burden, whereas tranexamic acid increases gastrointestinal toxicity without clear efficacy. Pharmacologic control of HHT-related epistaxis remains suboptimal, underscoring the need for adequately powered trials with standardized outcome measures and optimized dosing and delivery strategies.
2026-09-01 | Systemic bevacizumab for chronic bleeding and anemia in hereditary hemorrhagic telangiectasia: a retrospective cohort
Aim Anti-angiogenic therapy with bevacizumab has shown promise in hereditary hemorrhagic telangiectasia (HHT), although evidence remains limited. This retrospective cohort study evaluated bleeding severity, transfusion and iron requirements, anemia, and quality of life in patients receiving intravenous bevacizumab. Methods Eight patients with HHT receiving intravenous bevacizumab were included. Disease severity and health-related quality of life were assessed using the Epistaxis Severity Score (ESS) and SF-36 questionnaire, respectively. Results Five patients were female, and three were male, with a median follow-up of 30 months. The mean age was 65 years (range: 44-70). The mean ESS decreased from 7.75±2.7 to 1.4±1.2 after treatment. The median transfusion requirement declined from 5 units before treatment to none during the first 2 years. Median hemoglobin increased from 9.5 g/dL at baseline to 13.1, 14.55, 12.95, and 12.5 g/dL at 3, 6, 12, and 24 months, respectively. Mild headache and increased systolic blood pressure occurred in two patients each. All SF-36 scores improved after treatment. Conclusion In this small retrospective cohort, intravenous bevacizumab was associated with improved bleeding control, anemia, and quality-of-life outcomes, with no serious toxicity observed during follow-up
2026-08-26 | Topical Intranasal Treatments for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.
To characterize the landscape of topical intranasal therapies in hereditary hemorrhagic telangiectasia (HHT) associated epistaxis, evaluate comparative effectiveness versus placebo, and define their potential adjunctive role within evolving treatment paradigms. MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and the WHO-ICTRP were searched through May 2025. English-language studies of adults with HHT treated with topical agents for epistaxis were included. Study selection and data extraction were performed using Covidence in accordance with PRISMA guidelines. Risk of bias was assessed using Joanna Briggs Institute (JBI) checklists. Due to study heterogeneity, results were synthesized narratively. Of 310 records, 20 studies met inclusion (n = 590). Within-group reductions in Epistaxis Severity Score (ESS) were frequently observed; however, no topical class demonstrated consistent superiority over placebo in randomized controlled trials. Bevacizumab showed the largest reduction in ESS among case series (mean -3.3, n = 26). Across all agents, adverse events were uncommon and primarily limited to mild localized irritation. Current evidence does not support durable or clinically meaningful efficacy of topical intranasal monotherapy beyond placebo for HHT-related epistaxis. However, this absence of definitive efficacy reflects a structural evidence gap rather than a lack of biologic plausibility or patient-centered benefit. Given the phenotypic heterogeneity of HHT and the biologic variability in treatment response, topical agents remain clinically relevant as frontline adjunctive options for otolaryngologists managing this condition before systemic therapies become necessary. This review provides a framework for evidence-informed agent selection in the context of multimodal HHT care.
other
2026-01-24 | Beyond epistaxis: cascade screening and presymptomatic treatment of hereditary hemorrhagic telangiectasia.
Hereditary Hemorrhagic Telangiectasia is an autosomal dominant vascular disorder with clinical features of recurrent epistaxis, mucocutaneous telangiectasias, or visceral arteriovenous malformations, yet its early signs may be overlooked in children. We report a family in which a fifteen-year-old boy and his mother presented for genetic evaluation of recurrent epistaxis, after his previously well seven-year-old sister demised suddenly from likely spontaneous atraumatic intracranial hemorrhage (diagnosed clinically without confirmatory post-mortem imaging), following a brief history of headache and vomiting. The mother had a background of infrequent nosebleeds and a family history of recurrent epistaxis in multiple maternal relatives. Genetic testing identified heterozygosity for NM_001114753.3(ENG): c.1134G > A (p.Ala378=), a ClinVar classified pathogenic variant, confirming the diagnosis of hereditary hemorrhagic telangiectasia. Cascade testing for her two surviving children was done. Her fifteen-year-old son tested positive and was found on subsequent screening to have intracranial vascular malformations which were treated presymptomatically with gamma knife surgery. Her other son tested negative. This case emphasizes the importance of prompt recognition of hereditary hemorrhagic telangiectasia in children presenting with recurrent epistaxis and highlights the need for thorough family history. Pediatricians play a crucial role in early diagnosis and referral for genetic testing with subsequent surveillance imaging. Early identification may possibly reduce the risk of unfavorable outcomes such as intracranial hemorrhage. This case emphasizes the need for heightened awareness of hereditary hemorrhagic telangiectasia in pediatric practice and supports the value of integrating genetic cascade testing and organ-specific screening in at-risk children, even before symptoms appear.
2025-11-24 | An angiopoietin-2 vaccine improves arteriovenous malformation pathology in hereditary hemorrhagic telangiectasia mice.
Hereditary hemorrhagic telangiectasia (HHT) is a genetic vascular disorder that causes systemic arteriovenous malformations (AVMs) associated with severe complications. Angiopoietin (ANG)-2 has been identified as a consistently upregulated secreted protein across various HHT models, and neutralizing ANG2 reduces AVMs in mice. ANG2 has thus emerged as a potential target for HHT treatment. Here, we report the development of a peptide vaccine (ANG2-P3:CRM197) that selectively targets ANG2 over ANG1 and tested its effectiveness in decreasing retinal AVMs in neonatal mice injected with BMP9/10 blocking antibodies, a model of HHT. Litter groups from female C57BL/6 mice immunized with ANG2-P3:CRM197 received injections of anti-BMP9/10 antibodies, and their retinas were examined for vascular pathology. The potential toxicity of the vaccine was evaluated in females 12 months post-immunization through echocardiography, basic metabolic panels, and lipid profiles. Circulating anti-ANG2 antibodies were detected in nursing neonates of vaccinated females, with antibody levels comparable between litters and their dams, indicating effective antibody transfer from the dams. A significant decrease in AVM number and size was observed in the retinas of pups exposed to ANG2-P3:CRM197 antibodies compared to unexposed pups. Arterial and venous diameters were normalized in the vaccinated pups' retinas. The vaccinated females showed no abnormalities in cardiac, liver, or kidney functions. A vaccine strategy targeting ANG2 appears safe and improves AVM pathology in HHT mice. These findings further support the potential of inhibiting ANG2 as a viable approach for treating AVMs in HHT.
2025-08-29 | From Epistaxis to Embolization: A Case of Hereditary Hemorrhagic Telangiectasia Presenting With Spontaneous Hemothorax.
Hereditary hemorrhagic telangiectasia (HHT), or Rendu-Osler-Weber syndrome, is a rare autosomal dominant disorder characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs). We report a case of a 58-year-old female who presented with acute dyspnea and right-sided pleuritic chest pain. Her history included recurrent epistaxis since childhood and a positive family history of similar symptoms. Imaging revealed a right-sided hemorrhagic pleural effusion and pulmonary arteriovenous malformations (PAVMs), confirmed by CT pulmonary angiography and bubble contrast echocardiography. She underwent intercostal drainage followed by coil embolization of two large AVMs, with subsequent Amplatzer plug embolization on the contralateral side. Based on the Curacao criteria, a diagnosis of definite HHT was established. This case highlights hemothorax as a rare but potentially life-threatening initial manifestation of HHT. Early recognition, appropriate imaging, and timely embolization are essential to prevent recurrence and complications in patients with undiagnosed HHT presenting with pulmonary symptoms.
2024-10-26 | Red blood cell alloimmunization in transfused patients with hereditary hemorrhagic telangiectasia: A single centre retrospective study.
Hereditary hemorrhagic telangiectasia (HHT) is a genetic blood vessel disorder which may lead to chronic bleeding and red blood cell (RBC) transfusions. Data on transfusion requirements and complications in HHT patients are sparse. Retrospective chart review was conducted at St. Michael's Hospital (SMH) in Toronto, Canada. All adults with a definite clinical diagnosis of HHT AND inpatient hospital visits between January 1, 2011 and December 31, 2020 AND had undergone transfusion compatibility testing at SMH, were identified. Data were abstracted from electronic medical records. Simple descriptive statistics were used to analyze data. Institutional Research Ethics Board approval was obtained. 63 HHT patients underwent compatibility testing and were subsequently transfused at SMH. Median patient age at data abstraction was 70 years (Interquartile Range [IQR]: 18) and 35 (56 %) were female. RBC alloantibodies were found in 23 transfused patients (36.5 %) and were predominantly directed against Rh and Kell antigens: Anti-E (65 %), Anti-K (39 %) and Anti-c (22 %) were most common. Excluding an outlier who received 611 RBC units during the study period, the mean number of RBC units transfused per HHT patient at SMH was 22.1 units (Standard Deviation: 40.9, IQR: 17). Six (9.5 %) transfused patients experienced at least one transfusion reaction. RBC alloimmunization rate was 36.5 % in our cohort of transfused HHT patients; this is much higher than described in the general population and another transfused HHT cohort. The most commonly observed alloantibodies were Rh and Kell, supporting our policy of prophylactic phenotypic matching for these antigens for all transfused patients with HHT.
2024-09-17 | Catheter embolization for pulmonary arteriovenous malformations during chemotherapy for appendiceal adenocarcinoma: A case report of associated brain abscess.
Pulmonary arteriovenous malformations are rare, abnormal, low-resistance vascular structures that connect a pulmonary artery to a vein. They are common in patients with hereditary hemorrhagic telangiectasia; however, acquired malformations can occur in patients with underlying diseases such as chest trauma, hepatic cirrhosis, and mitral stenosis. Pulmonary arteriovenous malformations bypass the normal pulmonary capillary bed and result in intrapulmonary right-to-left shunts, which may cause central nervous system complications such as brain abscesses or ischemic stroke. Brain abscesses related to pulmonary arteriovenous malformations are not uncommon; however, reports of their occurrence during chemotherapy are limited. Here, we report the case of a 68-year-old woman with bilateral pulmonary arteriovenous malformations and appendiceal adenocarcinoma who developed a bacterial brain abscess during chemotherapy. The infection was treated using abscess drainage and antibiotic therapy. After the brain abscess healed, catheter embolization was performed on the pulmonary arteriovenous malformations and chemotherapy was resumed. The present case suggests that if a patient with a malignancy has a pulmonary arteriovenous malformation, clinicians should pay special attention to complications such as brain abscesses during chemotherapy. For patients who do not urgently need chemotherapy, embolization of the pulmonary arteriovenous malformation before chemotherapy may be a better treatment option.
proteins
2025-10-16 | Nasal RADA16 hydrogel application decreases epistaxis severity scores in adults with hereditary hemorrhagic telangiectasia.
More than 90% of adults with hereditary hemorrhagic telangiectasia (HHT) experience epistaxis, which can be recurrent and cause significant morbidity. RADA16 is a self-assembling peptide hydrogel approved by the US Food and Drug Administration for hemostasis and wound healing. In this cohort study, we assessed the effectiveness of nasal RADA16 application in controlling HHT-related epistaxis. A retrospective chart review was performed on a cohort of adult patients who received nasal RADA16 without any other changes in treatment. Pre- and post-Epistaxis Severity Scores (ESS), hemoglobin, and hematocrit were collected to assess treatment response. Of the included patients (n = 22), there were 26 applications of RADA16. The cohort was 54.5% male and 86.4% White, had a mean age of 55.5 years, and had a predominantly ACVRL1 genotype (40.9%). Baseline mean ESS was 5.0 and decreased by an average of 2.0 at an average of 46.9 days after treatment, which is 2.8 times more than the minimal clinically important difference for ESS in HHT (0.71). The mean baseline hemoglobin (n = 13) and hematocrit (n = 10), were 11.3 g/dL and 37.5%, respectively, and did not exhibit significant changes after RADA16 application. No bleeding, pain, or allergic reactions occurred due to the application. Several patients reported mild nasal congestion. Our experience demonstrates that RADA16 can be considered as a safe epistaxis treatment modality for HHT that is easy to apply and does not require the operating suite.
2025-06-24 | Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling.
Pulmonary arterial hypertension (PAH) and hereditary hemorrhagic telangiectasia (HHT) are two distinct vascular diseases linked to impaired signaling through bone morphogenetic protein (BMP) receptor complexes in endothelial cells. Although BMP-9 plays a central role in activating this pathway by binding to ALK1 and BMPR-II, its precise function in the pulmonary microvasculature has remained unclear. In this study, we demonstrate a role for BMP-9 in regulating pulmonary vascular architecture and homeostasis. Our findings reveal that BMP-9 signaling intersects with VEGF pathways and contributes to the delicate balance between vascular growth and remodeling in the lungs. We also show that disruption of this pathway can shift vascular responses toward an HHT-like state, potentially altering disease susceptibility. These insights offer a unique perspective on how BMP-9 and ALK1 shape pulmonary vascular biology and suggest that targeting this axis could inform future strategies for treating complex vascular diseases such as PAH.
2024-10-01 | 7819 Hypoglycemia with Hereditary Hemorrhagic Telangiextsia in a Boy After Liver Transplantation
Abstract Disclosure: H. Miyagi: None. M. Igarashi: None. E. Tanimoto: None. R. Horikawa: None. Introduction: Hereditary hemorrhagic telangiectasia (HHT) causes arteriovenous malformation (AVM) in liver, lung, and brain. It is not clear whether it also causes hypoglycemia. We show a case of HHT combined with hypoglycemia after liver transplantation, improved by nutrition management and growth hormone treatment. Case: 11 months old boy born from a mother with HHT was diagnosed as having with AVM prenatally. He was once operated for the liver AVM but developed a new collateral circulation which caused severe heart failure and lead to liver transplantation. He showed severe growth retardation and malnutrition. His body weight was 4.6 kg and height were 60 cm (-5.8 SD) when he was 1 year old, and blood test showed low albumin for 3 g/dL (3.4 - 4.7 g/dL), and total protein for 4 g/dL (5.7 - 7.5 g/dL). Hypoglycemia was found while switching his nutrition from parenteral to enteral nutrition after operation. His insulin was under 0.3 µU/mL when his blood glucose was 49 mg/dL IGF1 was 17 ng/mL (ref.11 - 149 ng/mL), suggested growth hormone (GH) deficiency. GH stimulation test showed blunted response. GH treatment was started. Other pituitary hormones were within normal range. Nutritional support was added using high-calory milk. After GH treatment, IGF1 level increased to 87 ng/mL. GH and nutritional management improved not only his weight and height gain but also his glycemic control. Discussion: Hypoglycemia may be caused by both GHD and malnutrition. GHD and low IGF1 might be caused by malnutrition. Retesting GH secretion after improvement of nutrition is planned to clarify his pituitary function. Presentation: 6/2/2024
2024-03-01 | Abstract 2385 The role of the ALK1 protein in vascular disease and potential targetability in Crohn's disease
The ACVRL1 gene is highly expressed in endothelial cells and encodes the transmembrane protein activin receptor-like kinase 1 (ALK1), which is a type I cell-surface receptor serine/threonine kinase for the transforming growth factor-β (TGF-β) superfamily of ligands BMP9/GDF2 and BMP10. ALK1 comprises of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular kinase domain. Upon ligand binding, this receptor forms complexes with other TGF-β receptors, primarily BMP9 to activate intracellular downstream signaling pathways. The Smad pathway functions to regulate gene expression through transmitting nucleus signals from the TGFβ receptors. Signaling is transmitted by a cytoplasmic kinase domain of ALK1 by phosphorylating receptor-regulated Smad proteins (R-Smad proteins). Activated R-Smad proteins and the common-Smad (co-Smad) form a complex to regulate transcription of target genes together with cofactors. This pathway is essential for angiogenesis and vasculogenesis and a mutation can induce several vascular diseases. The Smad Pathway is also crucial for endothelial cell differentiation and homeostasis, which plays roles in Crohn's Disease. Differing mutations in the ACVRL1 gene can result in increased or decreased kinase activity as well as impaired ligand binding, disrupting of TGF-β signaling, and in some cases induce a rare genetic disorder known as Hereditary Hemorrhagic Telangiectasia (HHT). HHT is an inherited disorder characterized by abnormally formed blood vessels. TGF-β can act as both a tumor suppressor and a tumor promoter, and mutations or dysregulation of components in its pathway can lead to several types of cancer. In Crohn's disease patients, scientists were able to determine an increased risk of endoscopic relapse based on ALK1 levels. Additionally, activation of ALK1 has been shown to enhance colonic intestinal epithelial barrier integrity and function ex vivo in these studies. The Walton High School SMART team, with support from 3D molecular designs, has modeled ALK1 receptors to support testing of the ALK1 protein to develop potential therapies and interventions for Crohn's disease, HHT, and several cancers.
2023-03-31 | Data from ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth
<div>Abstract<p>Activin receptor–like kinase-1 (ALK1) is a type I, endothelial cell–specific member of the transforming growth factor-β superfamily of receptors known to play an essential role in modulating angiogenesis and vessel maintenance. In the present study, we sought to examine the angiogenic and tumorigenic effects mediated upon the inhibition of ALK1 signaling using a soluble chimeric protein (ALK1-Fc). Of 29 transforming growth factor-β–related ligands screened by surface plasmon resonance, only bone morphogenetic protein (BMP9) and BMP10 displayed high-affinity binding to ALK1-Fc. In cell-based assays, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate. In a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor–, fibroblast growth factor–, and BMP10-mediated vessel formation. The growth of B16 melanoma explants was also inhibited significantly by ALK1-Fc in this assay. Finally, ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells. These data show the efficacy of chimeric ALK1-Fc proteins in mitigating vessel formation and support the view that ALK1-Fc is a powerful antiangiogenic agent capable of blocking vascularization. Mol Cancer Ther; 9(2); 379–</p></div>
small molecules
2026-09-24 | Decreased Endothelial Cell Retinoic Acid Signaling Accelerates Progression of Single Ventricle Pulmonary Vascular Malformations.
Pulmonary vascular malformations (PVMs) are vascular complications that universally develop in patients with single ventricle congenital heart disease after Glenn surgery, yet the pathogenesis of single ventricle PVMs remains unknown. Using a surgical rat model of Glenn circulation, single-cell RNA sequencing (scRNAseq) on whole lung samples identified dramatic endothelial cell (EC) gene expression changes post-surgery, including decreased all-trans retinoic acid (ATRA) signaling. Many gene expression differences (∼17% of all EC differentially expressed genes), including decreased ATRA signaling, were shared with 2 independent models of hereditary hemorrhagic telangiectasia arteriovenous malformations (AVMs). Subsequent dietary modification of vitamin A (Vit A) intake in rats, identified that dietary deficiency of Vit A increased PVM shunting severity, which was mitigated with excess dietary Vit A intake. Collectively, our study of post-Glenn PVMs identified shared patho-mechanisms with hereditary hemorrhagic telangiectasia AVMs, including decreased EC ATRA signaling, which is a novel potential target for treating AVMs.
2026-09-23 | Current Paradigm Shift in the Treatment of Hereditary Hemorrhagic Telangiectasia: A Narrative Review.
Background Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant, multisystem vascular disorder characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs). Pathogenic variants in ENG (endoglin), ACVRL1 (activin receptor-like kinase 1, ALK1), and SMAD4 (SMAD family member 4) disrupt signaling in the bone morphogenetic protein (BMP) 9/10 and transforming growth factor-beta (TGF-β) pathways, resulting in dysregulated angiogenesis and excess vascular endothelial growth factor (VEGF) activity. Clinically, HHT most commonly presents with recurrent epistaxis and chronic gastrointestinal (GI) bleeding, frequently leading to iron deficiency anemia and reduced quality of life (QoL). Complications from visceral AVMs involving the lungs, brain, and liver may also occur. Early diagnosis and systematic screening are essential to reduce preventable morbidity. Methods This narrative review synthesizes current primary literature on the diagnosis, screening, and treatment of HHT, with particular emphasis on evolving systemic therapies, supportive care strategies, and procedural interventions. Evidence from international guidelines, randomized trials, observational cohort studies, and narrowly focused systematic reviews was evaluated to summarize contemporary management approaches. Results HHT diagnosis is made with the Curaçao clinical criteria, genetic testing, and targeted imaging to identify visceral vascular malformations. Screening recommendations emphasize early detection of pulmonary and cerebral AVMs and ongoing surveillance for anemia and other complications. Therapeutic strategies increasingly prioritize systemic therapy over repeated local procedures. Antiangiogenic agents including intravenous bevacizumab, pomalidomide, thalidomide, and oral pazopanib have demonstrated efficacy in reducing bleeding severity, improving hemoglobin levels, and decreasing transfusion requirements in moderate-to-severe disease. Supportive care remains foundational and includes iron replacement, selective blood transfusion, routine monitoring, and assessment of patient-reported QoL. In patients with refractory epistaxis, surgical interventions such as septodermoplasty or nasal closure may provide durable bleeding control. Endovascular and neurosurgical management may also be required for selected vascular complications. Conclusions Management of HHT is undergoing a paradigm shift toward mechanism-based systemic therapy integrated with multidisciplinary care. Advances in antiangiogenic and precision-medicine approaches are improving bleeding control and long-term outcomes. Early recognition, comprehensive screening, individualized therapy, and coordinated management across specialties are critical for optimizing care in this complex multisystem disease.
2026-09-07 | Solving an enigma: the BMP-9/10 axis as a key regulator of pulmonary vascular resilience.
The circulating ligands bone morphogenetic protein (BMP)-9 and BMP-10 are emerging as dual regulators of pulmonary and systemic vascular biology. Acting through activin receptor-like kinase 1 (ALK1), BMP receptor type II (BMPRII) and endoglin receptor complexes, they maintain endothelial quiescence and vascular tone under physiological conditions. Yet, the same axis can turn pathogenic when its intensity, timing or cellular context are altered. We propose viewing BMP-9/10 not as a linear protective pathway but as a bimodal system in which both deficiency and hyperactivation disrupt vascular homeostasis, leading to distinct phenotypes such as obstructive pulmonary arterial remodeling in pulmonary arterial hypertension (PAH), intrapulmonary vasodilatation in hepatopulmonary syndrome (HPS), and arteriovenous shunting in hereditary haemorrhagic telangiectasia (HHT). The clinical success of sotatercept, an activin signaling inhibitor with partial BMP-ligand trap properties, underscores the translational potential of therapeutically "retuning" this pathway rather than globally enhancing it. Understanding when BMP-9/10 signaling protects and when it becomes pathogenic will be crucial for designing next-generation interventions that stabilize, instead of destabilize, pulmonary vascular integrity.
2026-09-01 | Interventional Radiology Management of Vascular Anomalies.
Vascular anomalies span a wide biological spectrum, from self-involuting infantile hemangiomas to life-threatening arteriovenous malformations. This review focuses on the conditions most commonly managed by interventional radiology, organized within the 2025 International Society for the Study of Vascular Anomalies classification framework. It covers the principles and agents of sclerotherapy for venous and lymphatic malformations, including comparative evidence for sclerosing agents, and embolization strategies for arteriovenous malformations and hereditary hemorrhagic telangiectasia -related pulmonary arteriovenous malformations. Also reviewed is the role of cryoablation in fibroadipose vascular anomaly, complex lymphatic anomaly management and the emerging techniques of bleomycin electrosclerotherapy and bleomycin electroembolotherapy.
2026-08-21 | Systemic therapies in hereditary hemorrhagic telangiectasia: Current evidence and emerging targets.
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant vascular disorder characterized by mucocutaneous telangiectases and visceral vascular malformations, leading to recurrent bleeding, iron-deficiency anemia, and organ complications. Pulmonary, cerebral, and hepatic involvement are major determinants of morbidity and mortality. Management has traditionally relied on local and interventional approaches, which are largely palliative and do not address underlying disease mechanisms. New insights in HHT pathophysiology, particularly in the dysregulated BMP9-BMP10/ENG/ALK1 pathway, which is fundamental to the angiogenesis process, have enabled the development of targeted systemic therapies. Although no systemic drug is specifically approved for HHT, antifibrinolytics, anti-angiogenic agents, mTOR and AKT inhibitors, and immunomodulatory drugs have shown variable efficacy in selected patients. This review summarizes current evidence on systemic therapies and ongoing clinical trials, highlighting their potential to complement existing strategies and move toward disease-modifying approaches.
gene therapies
2026-08-14 | Brain Abscess as the Initial Manifestation of Hereditary Hemorrhagic Telangiectasia in a Child.
Brain abscess secondary to pulmonary arteriovenous malformation is rare in children and may be the first manifestation of hereditary hemorrhagic telangiectasia (HHT). We retrospectively reviewed the clinical presentation, laboratory findings, imaging examinations, and diagnostic process of a child with brain abscess associated with pulmonary arteriovenous malformation and HHT. A 12-year-old boy presented with fever, headache, and limb weakness. Brain abscess was diagnosed, and antimicrobial therapy was initiated. Laboratory testing revealed fungal infection and erythrocytosis. Further evaluation identified a pulmonary arteriovenous malformation. Although the family history was initially unremarkable, physical examination revealed facial telangiectasia, recurrent epistaxis, and digital clubbing in his father, fulfilling the Curaçao criteria for HHT. Right-to-left shunt should be considered in children with brain abscess of unclear origin. Early recognition of underlying HHT is critical for timely diagnosis and management.
2026-07-07 | Expected survival is decreased in hereditary hemorrhagic telangiectasia: Results from a population-based registry study.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant genetic disorder associated with substantial morbidity. The aim of this study was to estimate mortality in a country without centralized national care for HHT patients. Moreover, we identified causes of death and estimated the prevalence of HHT in Sweden. The Swedish National Patient Register (NPR) was used to identify individuals with HHT using the International Classification of Diseases (ICD) code I78.0. Cases included all individuals with this code between January 1, 2001 and December 31, 2003 (n = 393). Five age- and gender-matched controls from the general population were selected by Statistics Sweden (SCB) (n = 1965). Cases and controls were followed for survival until 2018 using the Swedish National Cause of Death Register (DORS). To calculate prevalence, we identified all individuals with the ICD code I78.0 in the NPR over 12 years, from January 1, 2007 to December 30, 2018. Life expectancy for cases with HHT after age 30 was estimated at 73.0 (68.0-77.2) compared to 80.5 (79.1-82.0) years for controls. Ischemic heart diseases, diseases of arteries, arterioles, capillaries, and liver diseases were significantly more common causes of death among HHT patients. The prevalence of HHT was estimated at 9.3 per 100,000 over the 12 years. HHT in Sweden is associated with markedly shorter expected survival compared to the general population, and known complications of HHT are among the most common causes of death. The estimated prevalence of HHT in Sweden was relatively low, possibly due to underdiagnosis of those with milder symptoms.
2026-06-30 | When Phenotype Outspeaks Genotype: Uncommon Vascular Anomalies in Suspected Hereditary Hemorrhagic Telangiectasia Despite Negative Genetic Testing.
Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder characterized by abnormal blood vessel formation involving the skin and visceral organs. Establishing the diagnosis can be challenging, particularly in the absence of classic clinical manifestations or confirmatory genetic findings. We report the case of a 42-year-old woman who presented with acute epigastric pain and was found to have extensive vascular abnormalities involving the liver, lungs, aorta, and mesenteric circulation. She had no history of recurrent epistaxis, mucocutaneous telangiectasias, or family history of vascular disease, and genetic testing for known vascular disorders was negative. Despite the absence of typical clinical and genetic features, the distribution and extent of vascular involvement raised a strong suspicion for underlying HHT. This case highlights the potential for a broader phenotypic spectrum of HHT and underscores the limitations of current diagnostic criteria and genetic testing approaches.
2026-06-29 | Atypical Presentation of Hereditary Hemorrhagic Telangiectasia Without Recurrent Epistaxis Leading to Delayed Diagnosis
Objective:Unusual clinical course Background:Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disorder characterized by multisystem arteriovenous malformations (AVMs).The earliest symptoms often appear in childhood and typically encompass recurrent epistaxis.Severe outcomes, including cerebral hemorrhage and thrombotic complications, can increase morbidity and mortality.HHT is estimated to have near-complete penetrance, such that 97% of patients exhibit symptoms by age 60. Case Report:A 71-year-old man presented with a 1-month history of progressive shortness of breath, fatigue, dizziness, and lower-extremity edema.Further evaluation revealed severe iron-deficiency anemia (hemoglobin 6.4 g/dL, serum iron 21 µg/dL, total iron-binding capacity 462 µg/dL, transferrin saturation ~ 5%, and ferritin 13 ng/mL).He received 4 units of packed red blood cells, resulting in symptomatic improvement.Imaging did not identify any additional visceral malformations; follow-up esophagogastroduodenoscopy and colonoscopy findings were normal.Despite negative endoscopic findings, intermittent occult gastrointestinal blood loss remained the leading consideration given his prior history of bleeding gastrointestinal AVMs and laboratory findings consistent with iron-deficiency anemia.Capsule endoscopy-recommended to screen for small-bowel telangiectasias-was deferred.His medical history was notable for a delayed diagnosis of HHT.He remained clinically asymptomatic until age 67, when he developed spontaneous bilateral subdural hematomas and gastrointestinal bleeding. Conclusions:This case highlights delayed recognition of HHT in the absence of recurrent epistaxis, followed by serious intracranial and gastrointestinal complications.Overreliance on classic mucocutaneous features may contribute to diagnostic delay.Clinicians should consider HHT in older adults with otherwise unexplained AVM-related hemorrhage or anemia to facilitate timely screening and management.
2026-06-25 | A Novel Frameshift Variant of the ACVRL1 Gene in a Korean Family with Hereditary Hemorrhagic Telangiectasia Type 2: A Case Report
Beom Joon Kim, M.D., Woo Jin Shin, M.D., Hyunji Kim, M.D., Soohyun Seo, M.D., Anna Cho, M.D., Sook-Hyang Jeong, M.D., Kyoung Un Park, M.D.. Lab Med Online 2026;16:258-63. https://doi.org/10.47429/lmo.2026.16.3.258
antibodies
2026-09-29 | Severe Recurrent Gastrointestinal Bleeding Leading to the Diagnosis of Hereditary Hemorrhagic Telangiectasia: Clinical Response to Systemic Bevacizumab in a Case Report and Narrative Review.
Hereditary hemorrhagic telangiectasia (HHT), or Rendu-Osler-Weber disease, is an inherited vascular disorder that may cause severe gastrointestinal bleeding, particularly at an advanced age. The management of diffuse and recurrent gastrointestinal involvement may remain challenging despite repeated endoscopic treatments. We report the case of a 62-year-old woman with recurrent epistaxis since childhood, nasal and cutaneous telangiectases, and severe recurrent gastrointestinal bleeding related to multiple gastric, duodenal, jejunal, and more distal small-bowel telangiectases. A definite diagnosis of HHT was established based on the presence of three Curaçao criteria. During the two years preceding systemic therapy, the patient required 11 hospitalizations, repeated packed red blood cell transfusions, intravenous iron infusions, and 13 sessions of argon plasma coagulation. Intravenous bevacizumab was initiated at a dose of 5 mg/kg every 15 days for six induction cycles, followed by 5 mg/kg every four weeks as maintenance therapy. During one year of follow-up, the patient remained free of gastrointestinal bleeding for the first six months. The first recurrence occurred during the seventh month. Three separate hospitalizations for recurrent bleeding were observed during the year following bevacizumab initiation, compared with 11 during the preceding two years. The two most recent episodes were associated with less severe anemia than the most severe episodes before treatment. Qualitative endoscopic improvement, with an apparent reduction in the number and prominence of antral telangiectases, was also observed. No significant bevacizumab-related adverse events were identified. In this patient with severe HHT-related gastrointestinal involvement, systemic bevacizumab was associated with a clinically meaningful reduction in the overall bleeding burden. This case highlights the importance of considering HHT in patients with multiple or recurrent gastrointestinal telangiectases associated with epistaxis and mucocutaneous telangiectases.
2026-09-11 | A microphysiological system HHT-on-a-chip platform recapitulates patient vascular lesions.
Hereditary Hemorrhagic Telangiectasia (HHT) is a rare congenital disease in which fragile vascular malformations (VM) focally develop in multiple organs. There are few treatment options and no cure. HHT patients inherit loss-of-function mutations affecting Alk1-Eng signaling; however, why this manifests as VMs remains poorly understood. Here we have developed a fully human cell-based microphysiological system of perfused vasculature in which inducible shRNA controls endogenous Alk1 in primary endothelial cells (EC). Resulting VMs develop over several days, recapitulate patient VM appearance, and require only a subpopulation of Alk1-deficient EC to trigger lesions. Single-cell transcriptomics suggests microvessel pruning and regression contribute to VM, while loss of PDGFB implicates mural cell recruitment. Finally, pharmacological VEGF/VEGFR inhibition blocks lesion formation. In summary, we have developed an HHT-on-a-chip model that faithfully reproduces HHT patient lesions and that can be used to better understand HHT disease biology and identify potential new HHT drugs.
2026-09-11 | Efficacy and Safety of Various Medications in the Treatment of Hereditary Hemorrhagic Telangiectasia Epistaxis.
To compare the efficacy and safety of pharmacologic therapies for spontaneous epistaxis in hereditary hemorrhagic telangiectasia (HHT). PubMed, Scopus, Embase, Web of Science, and the Cochrane Library were systematically searched up to August 2025. Eligible randomized controlled trials evaluating bevacizumab, doxycycline, tranexamic acid, or β-blockers versus placebo or standard care were included. Outcomes included epistaxis frequency and duration, hemoglobin (Hb), epistaxis severity score (ESS), transfusion or emergent-care requirements, quality of life (QOL), and adverse events. Tranexamic acid did not significantly reduce epistaxis duration or frequency or improve Hb, and it did not change transfusion or emergent-care needs, but it increased diarrhea (odds ratio 3.8, 95% confidence interval [CI] [1.7; 8.5]). Bevacizumab produced a modest reduction in epistaxis frequency (standardized mean difference -0.25, 95% CI [-0.47; -0.02]), without significant effects on duration, ESS, Hb, or QOL. Doxycycline showed no significant benefit for duration or frequency. Topical or systemic β-blockers did not significantly affect ESS, QOL, Hb, or overall adverse events. Across agents, between-study heterogeneity was generally low to moderate and CIs were wide, reflecting limited sample sizes. No pharmacologic agent demonstrated consistent, clinically robust superiority over placebo across primary endpoints. Bevacizumab may modestly reduce bleeding burden, whereas tranexamic acid increases gastrointestinal toxicity without clear efficacy. Pharmacologic control of HHT-related epistaxis remains suboptimal, underscoring the need for adequately powered trials with standardized outcome measures and optimized dosing and delivery strategies.
2026-09-01 | Systemic bevacizumab for chronic bleeding and anemia in hereditary hemorrhagic telangiectasia: a retrospective cohort
Aim Anti-angiogenic therapy with bevacizumab has shown promise in hereditary hemorrhagic telangiectasia (HHT), although evidence remains limited. This retrospective cohort study evaluated bleeding severity, transfusion and iron requirements, anemia, and quality of life in patients receiving intravenous bevacizumab. Methods Eight patients with HHT receiving intravenous bevacizumab were included. Disease severity and health-related quality of life were assessed using the Epistaxis Severity Score (ESS) and SF-36 questionnaire, respectively. Results Five patients were female, and three were male, with a median follow-up of 30 months. The mean age was 65 years (range: 44-70). The mean ESS decreased from 7.75±2.7 to 1.4±1.2 after treatment. The median transfusion requirement declined from 5 units before treatment to none during the first 2 years. Median hemoglobin increased from 9.5 g/dL at baseline to 13.1, 14.55, 12.95, and 12.5 g/dL at 3, 6, 12, and 24 months, respectively. Mild headache and increased systolic blood pressure occurred in two patients each. All SF-36 scores improved after treatment. Conclusion In this small retrospective cohort, intravenous bevacizumab was associated with improved bleeding control, anemia, and quality-of-life outcomes, with no serious toxicity observed during follow-up
2026-08-26 | Topical Intranasal Treatments for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.
To characterize the landscape of topical intranasal therapies in hereditary hemorrhagic telangiectasia (HHT) associated epistaxis, evaluate comparative effectiveness versus placebo, and define their potential adjunctive role within evolving treatment paradigms. MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and the WHO-ICTRP were searched through May 2025. English-language studies of adults with HHT treated with topical agents for epistaxis were included. Study selection and data extraction were performed using Covidence in accordance with PRISMA guidelines. Risk of bias was assessed using Joanna Briggs Institute (JBI) checklists. Due to study heterogeneity, results were synthesized narratively. Of 310 records, 20 studies met inclusion (n = 590). Within-group reductions in Epistaxis Severity Score (ESS) were frequently observed; however, no topical class demonstrated consistent superiority over placebo in randomized controlled trials. Bevacizumab showed the largest reduction in ESS among case series (mean -3.3, n = 26). Across all agents, adverse events were uncommon and primarily limited to mild localized irritation. Current evidence does not support durable or clinically meaningful efficacy of topical intranasal monotherapy beyond placebo for HHT-related epistaxis. However, this absence of definitive efficacy reflects a structural evidence gap rather than a lack of biologic plausibility or patient-centered benefit. Given the phenotypic heterogeneity of HHT and the biologic variability in treatment response, topical agents remain clinically relevant as frontline adjunctive options for otolaryngologists managing this condition before systemic therapies become necessary. This review provides a framework for evidence-informed agent selection in the context of multimodal HHT care.
other
2026-01-24 | Beyond epistaxis: cascade screening and presymptomatic treatment of hereditary hemorrhagic telangiectasia.
Hereditary Hemorrhagic Telangiectasia is an autosomal dominant vascular disorder with clinical features of recurrent epistaxis, mucocutaneous telangiectasias, or visceral arteriovenous malformations, yet its early signs may be overlooked in children. We report a family in which a fifteen-year-old boy and his mother presented for genetic evaluation of recurrent epistaxis, after his previously well seven-year-old sister demised suddenly from likely spontaneous atraumatic intracranial hemorrhage (diagnosed clinically without confirmatory post-mortem imaging), following a brief history of headache and vomiting. The mother had a background of infrequent nosebleeds and a family history of recurrent epistaxis in multiple maternal relatives. Genetic testing identified heterozygosity for NM_001114753.3(ENG): c.1134G > A (p.Ala378=), a ClinVar classified pathogenic variant, confirming the diagnosis of hereditary hemorrhagic telangiectasia. Cascade testing for her two surviving children was done. Her fifteen-year-old son tested positive and was found on subsequent screening to have intracranial vascular malformations which were treated presymptomatically with gamma knife surgery. Her other son tested negative. This case emphasizes the importance of prompt recognition of hereditary hemorrhagic telangiectasia in children presenting with recurrent epistaxis and highlights the need for thorough family history. Pediatricians play a crucial role in early diagnosis and referral for genetic testing with subsequent surveillance imaging. Early identification may possibly reduce the risk of unfavorable outcomes such as intracranial hemorrhage. This case emphasizes the need for heightened awareness of hereditary hemorrhagic telangiectasia in pediatric practice and supports the value of integrating genetic cascade testing and organ-specific screening in at-risk children, even before symptoms appear.
2025-11-24 | An angiopoietin-2 vaccine improves arteriovenous malformation pathology in hereditary hemorrhagic telangiectasia mice.
Hereditary hemorrhagic telangiectasia (HHT) is a genetic vascular disorder that causes systemic arteriovenous malformations (AVMs) associated with severe complications. Angiopoietin (ANG)-2 has been identified as a consistently upregulated secreted protein across various HHT models, and neutralizing ANG2 reduces AVMs in mice. ANG2 has thus emerged as a potential target for HHT treatment. Here, we report the development of a peptide vaccine (ANG2-P3:CRM197) that selectively targets ANG2 over ANG1 and tested its effectiveness in decreasing retinal AVMs in neonatal mice injected with BMP9/10 blocking antibodies, a model of HHT. Litter groups from female C57BL/6 mice immunized with ANG2-P3:CRM197 received injections of anti-BMP9/10 antibodies, and their retinas were examined for vascular pathology. The potential toxicity of the vaccine was evaluated in females 12 months post-immunization through echocardiography, basic metabolic panels, and lipid profiles. Circulating anti-ANG2 antibodies were detected in nursing neonates of vaccinated females, with antibody levels comparable between litters and their dams, indicating effective antibody transfer from the dams. A significant decrease in AVM number and size was observed in the retinas of pups exposed to ANG2-P3:CRM197 antibodies compared to unexposed pups. Arterial and venous diameters were normalized in the vaccinated pups' retinas. The vaccinated females showed no abnormalities in cardiac, liver, or kidney functions. A vaccine strategy targeting ANG2 appears safe and improves AVM pathology in HHT mice. These findings further support the potential of inhibiting ANG2 as a viable approach for treating AVMs in HHT.
2025-08-29 | From Epistaxis to Embolization: A Case of Hereditary Hemorrhagic Telangiectasia Presenting With Spontaneous Hemothorax.
Hereditary hemorrhagic telangiectasia (HHT), or Rendu-Osler-Weber syndrome, is a rare autosomal dominant disorder characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs). We report a case of a 58-year-old female who presented with acute dyspnea and right-sided pleuritic chest pain. Her history included recurrent epistaxis since childhood and a positive family history of similar symptoms. Imaging revealed a right-sided hemorrhagic pleural effusion and pulmonary arteriovenous malformations (PAVMs), confirmed by CT pulmonary angiography and bubble contrast echocardiography. She underwent intercostal drainage followed by coil embolization of two large AVMs, with subsequent Amplatzer plug embolization on the contralateral side. Based on the Curacao criteria, a diagnosis of definite HHT was established. This case highlights hemothorax as a rare but potentially life-threatening initial manifestation of HHT. Early recognition, appropriate imaging, and timely embolization are essential to prevent recurrence and complications in patients with undiagnosed HHT presenting with pulmonary symptoms.
2024-10-26 | Red blood cell alloimmunization in transfused patients with hereditary hemorrhagic telangiectasia: A single centre retrospective study.
Hereditary hemorrhagic telangiectasia (HHT) is a genetic blood vessel disorder which may lead to chronic bleeding and red blood cell (RBC) transfusions. Data on transfusion requirements and complications in HHT patients are sparse. Retrospective chart review was conducted at St. Michael's Hospital (SMH) in Toronto, Canada. All adults with a definite clinical diagnosis of HHT AND inpatient hospital visits between January 1, 2011 and December 31, 2020 AND had undergone transfusion compatibility testing at SMH, were identified. Data were abstracted from electronic medical records. Simple descriptive statistics were used to analyze data. Institutional Research Ethics Board approval was obtained. 63 HHT patients underwent compatibility testing and were subsequently transfused at SMH. Median patient age at data abstraction was 70 years (Interquartile Range [IQR]: 18) and 35 (56 %) were female. RBC alloantibodies were found in 23 transfused patients (36.5 %) and were predominantly directed against Rh and Kell antigens: Anti-E (65 %), Anti-K (39 %) and Anti-c (22 %) were most common. Excluding an outlier who received 611 RBC units during the study period, the mean number of RBC units transfused per HHT patient at SMH was 22.1 units (Standard Deviation: 40.9, IQR: 17). Six (9.5 %) transfused patients experienced at least one transfusion reaction. RBC alloimmunization rate was 36.5 % in our cohort of transfused HHT patients; this is much higher than described in the general population and another transfused HHT cohort. The most commonly observed alloantibodies were Rh and Kell, supporting our policy of prophylactic phenotypic matching for these antigens for all transfused patients with HHT.
2024-09-17 | Catheter embolization for pulmonary arteriovenous malformations during chemotherapy for appendiceal adenocarcinoma: A case report of associated brain abscess.
Pulmonary arteriovenous malformations are rare, abnormal, low-resistance vascular structures that connect a pulmonary artery to a vein. They are common in patients with hereditary hemorrhagic telangiectasia; however, acquired malformations can occur in patients with underlying diseases such as chest trauma, hepatic cirrhosis, and mitral stenosis. Pulmonary arteriovenous malformations bypass the normal pulmonary capillary bed and result in intrapulmonary right-to-left shunts, which may cause central nervous system complications such as brain abscesses or ischemic stroke. Brain abscesses related to pulmonary arteriovenous malformations are not uncommon; however, reports of their occurrence during chemotherapy are limited. Here, we report the case of a 68-year-old woman with bilateral pulmonary arteriovenous malformations and appendiceal adenocarcinoma who developed a bacterial brain abscess during chemotherapy. The infection was treated using abscess drainage and antibiotic therapy. After the brain abscess healed, catheter embolization was performed on the pulmonary arteriovenous malformations and chemotherapy was resumed. The present case suggests that if a patient with a malignancy has a pulmonary arteriovenous malformation, clinicians should pay special attention to complications such as brain abscesses during chemotherapy. For patients who do not urgently need chemotherapy, embolization of the pulmonary arteriovenous malformation before chemotherapy may be a better treatment option.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
14 orphan drug designations for Hereditary hemorrhagic telangiectasia.
14 orphan drug designations for Hereditary hemorrhagic telangiectasia.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
Human bispecific monoclonal antibody targeting ALK1 and BMPRII | antibodies | EMA | Maxia Strategies-Europe Limited | |
BMPRII: ALK1 bispecific clustering agonist antibody | antibodies | FDA | Diagonal Therapeutics | |
6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one, L-tartrate salt | small molecules | EMA | FGK Representative Service GmbH | |
6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl) phenyl)-1-ethyl-7- phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one L-Tartrate salt | small molecules | FDA | Vaderis Therapeutics AG | |
Bevacizumab | antibodies | FDA | Laboratoires Delbert SAS | |
pazopanib | small molecules | FDA | HHT Foundation International (d/b/a Cure HHT) | |
Etamsylate | small molecules | EMA | Dobecure S.L. | |
thalidomide | small molecules | FDA | PlumeStars s.r.l. | |
Thalidomide | small molecules | EMA | PlumeStars s.r.l. | |
Bevacizumab | antibodies | EMA | Laboratoires Delbert | |
Bazedoxifene acetate | small molecules | EMA | — | Consejo Superior de Investigaciones Cientificas (CSIC) |
bevacizumab | antibodies | FDA | Terence M. Davidson, MD | |
raloxifene hydrochloride | small molecules | FDA | — | Consejo Superior de Investigaciones Cientificas |
Raloxifene hydrochloride | small molecules | EMA | — | Consejo Superior de Investigaciones Cientificas (CSIC) |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.